Challenge: | To address limited space and footprint constraints while meeting strict recycling standards set by regulatory boards. |
Solution: | QUA introduced EnviQ®24CV, an advanced submerged membrane bioreactor. This innovation automated operations, used durable PVDF membranes, and improved efficiency to consistently produce high-quality effluent meeting stringent standards. |
Result: | Since March 2022, the system has excelled, meeting all the client requirements. Stable water chemistry and a consistent permeate flow of 3 m3/hr showcase its ongoing success. |
This case study highlights the application of QUA’s pioneering membrane technology in tackling environmental hurdles within the pharmaceutical sector.
In response to stringent regulatory mandates from both the State and Central Pollution Control Boards in India, a leading pharmaceutical company recognized the pressing need to upgrade its effluent treatment system, focusing on recycling and reusing the treated water.
The client approached QUA, a division of Aquatech, to address the inherent complexities in treating pharmaceutical effluent effectively. One of the primary challenges was to enhance the existing conventional system within the constraints of limited available space and a restricted footprint.
QUA proposed and implemented the EnviQ® 24CV model, an innovative submerged membrane bioreactor (MBR) using flat sheet membrane technology. As part of their approach, the QUA team conducted a comprehensive audit of the existing facility, considering various input parameters such as the complexity of the effluent, spatial limitations, and issues related to the plant’s manual operation.
The EnviQ®24CV installation not only automated the operations but also ensured consistently high-quality product output, maintaining turbidity levels below 1NT. The utilization of robust and durable flat sheet PVDF membranes tailored to the facility's needs significantly improved operational and maintenance convenience while enhancing the overall reliability and efficiency of the MBR facility.
Since its successful implementation in March 2022, the EnviQ 24CV system has performed exceptionally well, meeting all the client’s requirements. The water chemistry has remained stable throughout this period, and the permeate flow has been maintained within the range of 3 m3/hr.
This project not only demonstrates the successful integration of cutting-edge technology but also highlights the importance of sustainable practices within the pharmaceutical industry; by effectively treating complex effluents and adhering to regulatory standards, the company has contributed to environmental conservation while maintaining operational efficiency.